QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.062182v1 308/3/935    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kang, J. Articles by Rampe, D. Search for Related Content PubMed PubMed Citation Articles by Kang, J. Articles by Rampe, D.

CARDIOVASCULAR

Cardiac Ion Channel Effects of Tolterodine

Departments of Drug Safety Evaluation (J.K., X.-L.C., H.W., J.J., W.R., D.R.) and Chemistry (S.L., J.H.), Aventis Pharmaceuticals, Bridgewater, New Jersey

Tolterodine is a muscarinic antagonist widely used in the treatment of urinary incontinence. Although tolterodine has not been reported to alter cardiac repolarization, it is chemically related to other muscarinic antagonists known to prolong cardiac repolarization. For this reason, we studied the effects of tolterodine on cardiac ion channels and action potential recordings. Using patch-clamp electrophysiology, we found that tolterodine was a potent antagonist of the human ether-a-go-go-related gene (HERG) K⁺ channel, displaying an IC₅₀ value of 17 nM. This potency was similar to that observed for the antiarrhythmic drug dofetilide (IC₅₀ of 11 nM). Tolterodine block of HERG displayed a positive voltage dependence, suggesting an interaction with an activated state. Tolterodine had little effect on the human cardiac Na⁺ channel at concentrations of up to 1 µM. Inhibition of L-type Ca²⁺ currents by tolterodine was frequency-dependent with IC₅₀ values measuring 143 and 1084 nM at 1 and 0.1 Hz, respectively. Both tolterodine and dofetilide prolonged action potential duration in single guinea pig myocytes over the concentration range of 3 to 100 nM. However, prolongation was significantly larger for dofetilide compared with tolterodine. Tolterodine seems to be an unusual drug in that it blocks HERG with high affinity, but produces little QT prolongation clinically. Low plasma levels after therapeutic doses combined with mixed ion channel effects, most notably Ca²⁺ channel blockade, may serve to attenuate the QT prolonging effects of this potent HERG channel antagonist.

Address correspondence to: Dr. David Rampe, Aventis Pharmaceuticals, Route 202-206, P.O. Box 6800, Room JR2-2236, Bridgewater, NJ 08807-0800. E-mail: david.rampe{at}aventis.com

This article has been cited by other articles:

				J. Kang, X.-L. Chen, H. Wang, J. Ji, H. Cheng, J. Incardona, W. Reynolds, F. Viviani, M. Tabart, and D. Rampe Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel Mol. Pharmacol., March 1, 2005; 67(3): 827 - 836. [Abstract] [Full Text] [PDF]